BioSante Pharmaceuticals today announced that its common stock has begun trading on the American Stock Exchange under the ticker symbol BPA.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for topical administration that deliver bioidentical estradiol and testosterone.

Symptoms treated with hormone therapy in men include impotence, diminished drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, atrophy, decreased drive and osteoporosis. The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales. BioSante also is developing its calcium phosphate nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems.

"We are pleased to welcome BioSante to the American Stock Exchange," said John McGonegal, vice president of the Amex Equities Group. "We look forward to working with BioSante on their continued commitment to creating shareholder value by building upon their solid innovation within the biopharmaceutical industry."

"We are delighted with our move to the American Stock Exchange and its considerable support structure," said Stephen M. Simes, president and chief executive officer of BioSante. "We believe our American Stock Exchange listing will result in a broader base of investors and provide additional liquidity and value to BioSante's stockholders as we continue to develop new products."

BioSante will be represented by the specialist firm of Cohen Specialists LLC on the Amex trading floor.